linjc16/ctgov huggingface dataset:
Effectiveness of Early Detection of Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
To verify if the screening opportunistic of Atrial Fibrillation (AF) by means of the measurement of the arterial peripheral pulse is more effective than the habitual practice for the early detection of AF in 65-year-old who come to Primary care

Official Title
-----------------
Effectiveness of Early Detection of Atrial Fibrillation in People 65 Years or More bt Physicians and Nurse in Primary Care

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Screening
* Procedure: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that come to his center of health for any motive. That give his assent informed to take part in the study. Exclusion Criteria: FA previous Diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Screening<br>Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular | Procedure: Screening<br>* Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG<br>* Other names: Asymptomatic patient;|
| Active Comparator: Control<br>Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular | Procedure: Control<br>* Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG<br>* Other names: Symptomatic patient;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy of screening: number of cases diagnosed of Atrial fibrillation (AF) | Risk Relative (RR)=number of cases of AF with the Screening/number of cases of AF with the habitual intervention | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, screening, prevention, case finding, primary care
Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
In the literature, there are no studies evaluating fear of COVID-19, anxiety, depression, physical activity, fear of movement and quality of life in patients with chronic kidney disease during COVID-19 pandemic. The investigators will evaluate these parameters in patients with chronic kidney disease and compare the findings of healthy individuals during COVID-19 pandemic

Official Title
-----------------
Fear of COVID-19 and Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic

Conditions
-----------------
Covid19, Chronic Kidney Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having been diagnosed with chronic kidney disease Being clinically stable Volunteering to participate in the research Exclusion Criteria: Having a cognitive problem Not being literate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with chronic kidney disease<br>Having been diagnosed with chronic kidney disease | |
| Healthy individuals<br>Healthy individuals without chronic disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fear of COVID-19 | COVID-19 phobia will be evaluated using Fear of COVID-19 Scale. | 5 minutes | 
| Physical activity | Physical activity level will be evaluated using International Physical Activity Questionnaire - Short Form (IPAQ-SF). | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qol | Quality of life will be evaluated using SF-36 | 10 minutes | 
| Anxiety and depression | Anxiety and depression will be evaluated using Hospital Anxiety and Depression scale (HADS). | 5 minutes | 
| Fear of movement | Fear of movement will be evaluated using the Tampa Scale for Kinesiophobia | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fear, Quality of life, Anxiety, Depression
Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

Study Overview
=================
Brief Summary
-----------------
This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

Official Title
-----------------
A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Daglutril


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sitting office diastolic blood pressure between 90 and 109 mmHg office systolic blood pressure between 140 and 179 mmHg mean day-time diastolic 24-h ABPM blood pressure >= 85 mmHg inclusive at baseline Exclusion Criteria: known secondary hypertension decompensated congestive heart failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Daglutril|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood pressure
Autonomy Among Physically Frail Older People in Nursing Homes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the status of perceived autonomy and to evaluate the effectiveness of individually tailored programmes on perceived autonomy in physically frail older people living in nursing homes.

Detailed Description
-----------------
Experiencing autonomy is recognised to promote health and well-being for all age groups. Perceived lack of control has been found to be detrimental to physical and mental health. There is a lack of evidence-based knowledge elucidating how frail older people in nursing home settings perceive autonomy. Further, there are no studies on the extent to which this perception can be influenced positively by participating in an individually tailored programme based on individual wishes for daily activities. The purpose of this study was to evaluate the effectiveness of individually tailored programmes on perceived autonomy in physically frail older people in nursing homes.

Official Title
-----------------
Autonomy Among Physically Frail Older People in Nursing Homes: a Study Protocol for an Intervention Study

Conditions
-----------------
Frailty

Intervention / Treatment
-----------------
* Other: Individually tailored programmes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 65 years or older All kinds of diseases leading to physical frailty Dependent on assistance in minimum one P-ADL activity Able to understand verbal instructions Willing to participate Expected to live in the nursing home during the 24 weeks Both men and women Exclusion Criteria: Terminal stages of disease MMSE-score below 16

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive. | Other: Individually tailored programmes<br>* Individualised intervention programmes based on individual wishes for daily activities<br>* Other names: autonomy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Autonomy Sub-dimension |  | baseline, after 12 weeks, anfter 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autonomy, Older people, Physically frail, Nursing home, Intervention study
Internal Carotid Artery Blood Flow in Infants With Prone Position

Study Overview
=================
Brief Summary
-----------------
Little is known about how implementation of prone position contributes to general anesthesia-induced decrease in cerebral blood flow in infants. The investigators investigated this question in participants undergoing untethering, hypothesizing that cardiorespiratory changes during this procedure would reduce cerebral perfusion.

Official Title
-----------------
A Study on Internal Carotid Artery Blood Flow Velocity Changes in Prone, Head Tilt and Trendelenberg Position in Infants: an Observational Study Using Transfontanel Ultrasound

Conditions
-----------------
Cerebral Lesion

Intervention / Treatment
-----------------
* Other: ultrasound assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric neurosurgical patients receiving surgery under prone position Exclusion Criteria: patients diagnosed as hydrocephalus premature closure of fontanelle patients diagnosed as patent ductus arteriosus or other congenital heart disease.

Ages Eligible for Study
-----------------
Maximum Age: 15 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of internal carotid artery blood flow velocity |  | from induction of anesthesia to end of operation, about 3 hours |
Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
To assess the predictive value of circulating tumor cells (CTCs) for recurrence of advanced gastric cancer after radical resection. To identify the relationship between the detection of circulation tumor cells and recurrence patterns of gastric cancer after radical resection.

Official Title
-----------------
Prediction of Recurrence in Advanced Gastric Cancer After Radical Resection by Circulating Tumor Cells （CTCs）

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Other: detection of CTCs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having signed informed consent Age≥ 18 years old Histologically confirmed gastric adenocarcinoma Preoperative clinical examination and imaging indicating operable disease complete resection (R0 resection) D2 or D2+ resection Exclusion Criteria: Other tumor type than adenocarcinoma Patients who have been given preoperative chemotherapy/chemoradiation. Staging investigations or intraoperative exploration indicating inoperable disease R1 or R2 resection D0 or D1 resection Patients unreliable for follow up Past history of malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CTCs positive<br> | Other: detection of CTCs<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CTCs |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of gastric cancer after radical resection |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CTCs before and after gastrectomy
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.

Detailed Description
-----------------
Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52 weeks. PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.

Official Title
-----------------
A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial (With Open-Label AZT) to Evaluate the Safety and Efficacy of Low Dose 3TC Administered Concurrently With AZT Versus High Dose 3TC Administered Concurrently With AZT Versus ddC Administered Concurrently With AZT in the Treatment of HIV-1 Infected, AZT-Experienced (>= 24 Weeks) Patients With CD4 Counts of 100-300 Cells/mm3

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Lamivudine
* Drug: Zidovudine
* Drug: Zalcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV positivity. CD4 count 100-300 cells/mm3. Prior AZT therapy for 24 or more weeks and currently on AZT. Exclusion Criteria Patients with the following prior conditions are excluded: History of intolerance to AZT. History of grade 2 or worse peripheral neuropathy. Prior Medication: Excluded: Any prior antiretroviral therapy other than AZT. Required: Concomitant AZT therapy. Required: At least 24 weeks of prior AZT.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lamivudine|nan|
|Drug: Zidovudine|nan|
|Drug: Zalcitabine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Zalcitabine, Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Zidovudine
Biomarkers In Retinitis Pigmentosa (BIRP)

Study Overview
=================
Brief Summary
-----------------
In this study, markers of oxidative stress will be measured in the aqueous humour and plasma of RP patients compared to controls.

Detailed Description
-----------------
People with Retinitis Pigmentosa have loss of night vision followed by loss of central vision due to damage and death of photoreceptors. One of the mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific biomarkers which can be measured. In this study, these biomarkers will be assessed in people with Retinitis Pigmentosa and compared to controls.

Official Title
-----------------
Biomarkers In Retinitis Pigmentosa (BIRP)

Conditions
-----------------
Retinitis Pigmentosa

Intervention / Treatment
-----------------
* Other: Anterior Chamber (AC) tap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent and authorization of use and disclosure of protected health information Age more than or equal to 18 years For the study group, patients diagnosed with Retinitis Pigmentosa by the investigators For the control group, patients undergoing vitreoretinal surgery for macular hole, epiretinal membrane, vitreomacular traction, retinal detachment, neovascular Age-related Macular Degeneration (AMD) and Diabetic Retinopathy will be eligible Exclusion Criteria: Patients with active or suspected ocular or periocular infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RP patients<br>Retinitis Pigmentosa patients | Other: Anterior Chamber (AC) tap<br>* Aqueous Samples will be collected for measurement of biomarkers<br>|
| Controls<br>Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy. | Other: Anterior Chamber (AC) tap<br>* Aqueous Samples will be collected for measurement of biomarkers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aqueous levels of markers of oxidative stress in patients with RP and controls. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RP
Dermatological Evaluation of Topic Compatibility - Dermacyd Breeze

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the absence of irritation potential (primary dermal irritability and cumulated dermal irritability) and allergy (sensibilization) of the product Dermacyd Pocket BR.

Official Title
-----------------
Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Breeze.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Lactic acid (Dermacid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Phototype Skin I,II, III e IV Integral skin test in the region Exclusion Criteria: Use of Antiinflammatory and/or immunosuppression drugs Personnel history of atopy History of sensitivity or irritation for topic products Active cutaneous disease Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lactic acid (Dermacid)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The absence of primary and accumulated dermal irritability and dermal sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale. |  | six weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hygiene